Key Market Players Profiled include Illumina, Qiagen, PerkinElmer, F. Hoffmann-La Roche, Thermo Fisher Scientific, Natera, Bio-Rad Laboratories, Adaptive Biotechnologies, Sysmex, Integrated DNA ...

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have ...

Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, ...

Is there a cure for multiple myeloma, how do I know it’s gone? Some people are able to stop treatment for multiple myeloma because of something called minimal residual disease (MRD). MRD negativity ...

Autologous hematopoietic stem cell transplantation did not improve outcomes for patients with mantle cell lymphoma and undetectable minimal residual disease.

Renovaro Inc. announces funding approval for LUMINA, a platform detecting minimal residual disease in lung cancer using multi-omics and AI. Renovaro Inc. announced that its subsidiary ...

Johnson & Johnson “announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI significantly increased minimal residual disease, MRD, negativity rates in ...

Researchers sought to determine if HRQoL measures differ with gilteritinib compared with placebo in patients with AML.

Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, ...

The decision greenlights a new biomarker endpoint, minimal residual disease, for accelerated drug approval in multiple myeloma, and researchers say it could cut a decade off the drug development ...

The finding is from the phase 3 study EA4151, Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete ...